Cytosorbents CorpCTSO
Market Cap: 55.9M
About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Employees: 186
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0.78% less ownership
Funds ownership: 34.36% [Q4 2023] → 33.58% (-0.78%) [Q1 2024]
6% less funds holding
Funds holding: 52 [Q4 2023] → 49 (-3) [Q1 2024]
16% less capital invested
Capital invested by funds: $19.9M [Q4 2023] → $16.6M (-$3.26M) [Q1 2024]
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
B. Riley Securities Yuan Zhi | 191%upside $3 | Buy Reiterated | 15 May 2024 |
HC Wainwright & Co. Sean Lee | 3%downside $1 | Neutral Reiterated | 7 May 2024 |
HC Wainwright & Co. Sean Lee | 3%downside $1 | Neutral Reiterated | 15 Mar 2024 |